» Articles » PMID: 34920723

Impact of Rewarming Rate on Interleukin-6 Levels in Patients with Shockable Cardiac Arrest Receiving Targeted Temperature Management at 33 °C: the ISOCRATE Pilot Randomized Controlled Trial

Overview
Journal Crit Care
Specialty Critical Care
Date 2021 Dec 18
PMID 34920723
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: While targeted temperature management (TTM) has been recommended in patients with shockable cardiac arrest (CA) and suggested in patients with non-shockable rhythms, few data exist regarding the impact of the rewarming rate on systemic inflammation. We compared serum levels of the proinflammatory cytokine interleukin-6 (IL6) measured with two rewarming rates after TTM at 33 °C in patients with shockable out-of-hospital cardiac arrest (OHCA).

Methods: ISOCRATE was a single-center randomized controlled trial comparing rewarming at 0.50 °C/h versus 0.25 °C/h in patients coma after shockable OHCA in 2016-2020. The primary outcome was serum IL6 level 24-48 h after reaching 33 °C. Secondary outcomes included the day-90 Cerebral Performance Category (CPC) and the 48-h serum neurofilament light-chain (NF-L) level.

Results: We randomized 50 patients. The median IL6 area-under-the-curve was similar between the two groups (12,389 [7256-37,200] vs. 8859 [6825-18,088] pg/mL h; P = 0.55). No significant difference was noted in proportions of patients with favorable day-90 CPC scores (13/25 patients at 0.25 °C/h (52.0%; 95% CI 31.3-72.2%) and 13/25 patients at 0.50 °C/h (52.0%; 95% CI 31.3-72.2%; P = 0.99)). Median NF-L levels were not significantly different between the 0.25 °C/h and 0.50 °C/h groups (76.0 pg mL, [25.5-3074.0] vs. 192 pg mL, [33.6-4199.0]; P = 0.43; respectively).

Conclusion: In our RCT, rewarming from 33 °C at 0.25 °C/h, compared to 0.50 °C/h, did not decrease the serum IL6 level after shockable CA. Further RCTs are needed to better define the optimal TTM strategy for patients with CA. Trial registration ClinicalTrials.gov, NCT02555254 . Registered September 14, 2015.

Take-home Message: Rewarming at a rate of 0.25 °C/h, compared to 0.50 °C, did not result in lower serum IL6 levels after achievement of hypothermia at 33 °C in patients who remained comatose after shockable cardiac arrest. No associations were found between the slower rewarming rate and day-90 functional outcomes or mortality. 140-character Tweet: Rewarming at 0.25 °C versus 0.50 °C did not decrease serum IL6 levels after hypothermia at 33 °C in patients comatose after shockable cardiac arrest.

Citing Articles

Chinese clinical practice consensus for device-supported treatment in adults with post-cardiac arrest syndrome (2024 Edition).

Li C, Cao S, Zheng Y, Zong M, Zhang H, Yu X World J Emerg Med. 2025; 16(1):3-9.

PMID: 39906098 PMC: 11788105. DOI: 10.5847/wjem.j.1920-8642.2025.019.


Rapid rewarming rate associated with favorable neurological outcomes in patients with post-cardiac arrest syndrome patients treated with targeted temperature management.

Shin M, Fujita M, Hifumi T, Koga Y, Yagi T, Nakahara T Acute Med Surg. 2023; 10(1):e897.

PMID: 37841965 PMC: 10568044. DOI: 10.1002/ams2.897.


Serum neurofilament light chain as a predictive marker of neurologic outcome after cardiac arrest: a meta-analysis.

Wang S, Li N, Feng S, Li Y BMC Cardiovasc Disord. 2023; 23(1):193.

PMID: 37061702 PMC: 10105388. DOI: 10.1186/s12872-023-03220-z.


Temperature Control After Cardiac Arrest: A Narrative Review.

Fernandez Hernandez S, Barlow B, Pertsovskaya V, Maciel C Adv Ther. 2023; 40(5):2097-2115.

PMID: 36964887 PMC: 10129937. DOI: 10.1007/s12325-023-02494-1.


Cytokine hemoadsorption with CytoSorb in post-cardiac arrest syndrome, a pilot randomized controlled trial.

Monard C, Bianchi N, Poli E, Altarelli M, Debonneville A, Oddo M Crit Care. 2023; 27(1):36.

PMID: 36691082 PMC: 9869834. DOI: 10.1186/s13054-023-04323-x.


References
1.
Chong J, Ahn H, Park J, You Y, Min J, Jeong W . Interleukin-6 as a Potential Predictor of Neurologic Outcomes in Cardiac Arrest Survivors Who Underwent Target Temperature Management. J Emerg Med. 2020; 59(6):828-835. DOI: 10.1016/j.jemermed.2020.09.021. View

2.
Borm G, Fransen J, Lemmens W . A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol. 2007; 60(12):1234-8. DOI: 10.1016/j.jclinepi.2007.02.006. View

3.
Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C . Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013; 369(23):2197-206. DOI: 10.1056/NEJMoa1310519. View

4.
Lemiale V, Dumas F, Mongardon N, Giovanetti O, Charpentier J, Chiche J . Intensive care unit mortality after cardiac arrest: the relative contribution of shock and brain injury in a large cohort. Intensive Care Med. 2013; 39(11):1972-80. DOI: 10.1007/s00134-013-3043-4. View

5.
Lascarrou J, Le Gouge A, Dimet J, Lacherade J, Martin-Lefevre L, Fiancette M . Neuromuscular blockade during therapeutic hypothermia after cardiac arrest: observational study of neurological and infectious outcomes. Resuscitation. 2014; 85(9):1257-62. DOI: 10.1016/j.resuscitation.2014.05.017. View